clinical trial · NCT03680131
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
Allergic Contact DermatitisEB01 Cream PlaceboEB01 Cream 0.2%EB01 Cream 1.0%EB01 Cream 2.0%
brief summary
The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of moderate to severe chronic allergic contact dermatitis (ACD). The purpose of the open label extension is to assess the long-term safety, tolerability, and efficacy of EB01 2.0% cream in subjects with moderate to severe chronic allergic contact dermatitis.
started
Oct 15, 2019
primary completion
Sep 21, 2022
completion
Jan 17, 2023
last updated
Nov 14, 2024
official title
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol